Recurrence of C3 Glomerulopathy and Immune Complex–Mediated Membranoproliferative Glomerulonephritis After #Kidney #Transplantation: Challenges and Opportunities

https://doi.org/10.1016/j.ekir.2025.11.008

#C3Glomerulopathy #KIRReview

Hierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic #MPGN and #C3glomerulopathy

doi.org/10.1016/j.kint.2025.08.035

#MedSky #NephSky #OpenAccess #kidneydisease

A New Era for C3G Treatment with Pegcetacoplan In part 1 of this 5-part HCPLive RX Review, experts discuss the current therapeutic landscape for C3G following 2 notable FDA approvals.

What does the approval of pegcetacoplan mean for nephrologists? Our expert panel breaks down their perspectives in a recent RX Review: www.hcplive.com/view...

#Nephrology #C3Glomerulopathy

Quantifying association of early proteinuria and estimated GFR changes with long-term kidney failure in #C3glomerulopathy and immune-complex membranous proliferative #glomerulonephritis using the United Kingdom RaDaR Registry

doi.org/10.1016/j.kint.2025.06.003

#OpenAccess #NephSky #MedSky

Iptacopan Becomes First Approved Therapy for C3G | Docwire News Oral iptacopan (Fabhalta) has become the first FDA-approved treatment for proteinuria in adults with C3 glomerulopathy (C3G).

⚠️ The FDA has approved oral iptacopan to treat proteinuria in adults with C3 glomerulopathy. This is the first FDA-approved treatment for C3G. #fda #c3glomerulopathy #c3g #kidneydisease #nephrology #nephsky

Enjoy👌#podocyte #puzzles #c3glomerulopathy